Clinical Trial Update: A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer [Phase 1]

View source ↗

Summary

Phase 1 study to determine a safe and potentially effective dose of BI-905711 in patients with advanced gastrointestinal cancers, including cholangiocarcinoma. …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Gastrointestinal Cancer
• Pancreatic Cancer

Drugs mentioned

• BI-905711

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Gastrointestinal Neoplasms, Cholangiocarcinoma | Phase 1 | Status: COMPLETED | Results posted: 2025-03-25